Prevalence and characteristics of monogenic disease in adult kidney stone formers

Manuel A. Anderegg[1,2,#], Eric G. Olinger[1,2,3,4,#], Matteo Bargagli[1,2], Rob Geraghty[3], Lea Pohlmeier[5], Alexander Nater[5], Rémy Bruggmann[5], John A. Sayer[3,6,7], Bruno Vogt[1], André Schaller[8,#], Daniel G. Fuster[1,2,#,*]

[1]Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Switzerland

[2]Swiss National Centre of Competence in Research (NCCR) Kidney.CH

[3]Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK

[4]Center for Human Genetics, Cliniques Universitaires Saint-Luc, Brussels, Belgium

[5]Interfaculty Bioinformatics Unit, University of Bern and Swiss Institute of Bioinformatics (SIB), Switzerland

[6]Renal Services, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

[7]National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle Upon Tyne, NE4 5PL UK.

[8]Department of Human Genetics, Inselspital, Bern University Hospital, University of Bern, Switzerland Switzerland

# Contributed equally

* Address correspondence to:

Daniel G. Fuster

Department of Nephrology and Hypertension,

Inselspital, Bern University Hospital, University of Bern,

Freiburgstrasse 15, 3010 Bern, Switzerland

Email: daniel.fuster@insel.ch

Phone: ++41 (0)31 632 31 44

Fax: ++41 (0)31 632 37 37

Keywords: Kidney stones, nephrolithiasis, monogenic, mendelian, whole exome sequencing

ABSTRACT

Molecular mechanisms of kidney stone formation remain unknown in most patients. Previous studies showed a high heritability of nephrolithiasis, but data on prevalence and characteristics of monogenic disease in unselected adults with nephrolithiasis are lacking.

We performed whole exome sequencing in 787 participants of the Bern Kidney Stone Registry, an unselected cohort of adults with ≥ 1 past kidney stone episode (KSF), and 114 non-stone-forming individuals (NKSF). A panel of 34 established nephrolithiasis genes was analyzed and variants were assessed according to ACMG criteria. Pathogenic or likely pathogenic variants were considered diagnostic.

Mean age of KSF was 47±15 years, and 18 % were first time KSF. A monogenic kidney stone disease was present in 8.4 % (66 of 787) of KSF and in 0.9 % (1 of 114) of NKSF. The most common genetic diagnoses were cystinuria (*SLC3A1*, *SLC7A9*; n=16), renal phosphate wasting *(SLC34A1* or *SLC34A3*; n=20), Vitamin D-24 hydroxylase deficiency (*CYP24A1*; n=13) and renal magnesium wasting with hypercalciuria (*CLDN16*; n=8). KSF with monogenic disease had a lower mean age at the first stone event (30±14 years vs. 36±14 years, p=0.003), were more likely to have cystine stones (23.4 % vs. 1.4 %) and less likely to have calcium oxalate monohydrates stones (31.9 % vs. 52.5 %) compared to KSF without genetic diagnosis. All other clinical parameters were similar between the two groups.

Thus, monogenic disease is prevalent in unselected adult KSF. The usefulness of clinical parameters for the prediction of monogenic disease is limited in adult KSF.

INTRODUCTION

Nephrolithiasis is a common global healthcare problem [1]. Kidney stones recur frequently and cause substantial morbidity, reduced quality of life and enormous cost [2-4]. Most kidney stones are classified as "idiopathic", indicating that the pathogenesis is unclear. Consequently, undifferentiated dietary and pharmacological preventive measures are initiated, but many patients continue to form stones [5,6]. Hence, our current strategies in managing this very common and relapsing disease are clearly inadequate. There is an unmet need for novel diagnostic and therapeutic approaches.

Kidney stone formation is strongly influenced by genetic factors: a positive family history is present in 30-60% of individuals with kidney stones [7], and both twin [8] and genealogy [9] studies revealed a high heritability of nephrolithiasis. More than 30 monogenic causes of nephrolithiasis have been described thus far [10]. Recognition of monogenic disease is essential for accurate genetic counseling, informed decision making by families and physicians and access to appropriate medical support and services [11]. Furthermore, the pathophysiology is well defined in most cases and amenable to causal interventions that directly target the pathogenesis at the molecular level, enabling tailored precision medicine approaches in affected patients. However, identification of patients with Mendelian forms of nephrolithiasis remains a major challenge, and no consensus exists on clinical parameters to guide genetic testing. As a result, most diagnoses of monogenic nephrolithiasis are missed and incorrectly labelled "idiopathic".

Whole exome sequencing (WES) is widely applied as diagnostic tool for rare diseases and the detection of pathogenic variants in cancer [11,12]. In contrast, the diagnostic utility of WES has not been established for most constitutional disorders in adults, such as nephrolithiasis. In small, selected cohorts of early-onset or familial nephrolithiasis, a monogenic cause was identified in 6.8 - 29.4% of cases [10,13-15]. However, the frequency of monogenic disease in sporadic adult-onset nephrolithiasis, by far the most common type encountered in clinical routine, is unknown.

Further, due to small sample size and lack of detailed phenotypes, clinical characteristics associated with monogenic kidney stone disease are poorly defined. To address these important knowledge gaps, we employed WES in a deeply phenotyped, unselected European cohort of 787 adult kidney stone formers (KSF) and in 114 non stone-forming controls (NKSF).

METHODS

Study cohort and phenotypic analysis

The study was conducted with participants enrolled in the Bern Kidney Stone Registry (BKSR). The BKSR is an observational cohort of adult kidney stone formers recruited at the Department of Nephrology and Hypertension, Bern University Hospital, Bern, Switzerland. All kidney stone formers, including first-time stone formers, referred for metabolic work-up are invited to participate in the BKSR. The BKSR adheres to the Declaration of Helsinki and was approved by the ethical committee of the Kanton of Bern (approval # BE 95/06). Inclusion criteria for the BKSR are i) written informed consent, ii) age ≥ 18 years, and iii) ≥ 1 past kidney stone episode [16-19]. There were no pre-specified exclusion criteria. BKSR participants underwent a detailed metabolic work-up under free choice diet and thereafter 1 week of instructed low–calcium (15–20 mmol/d) and low–sodium (100 mmol/d) diet [16-21]. Blood and urine analyses were performed at the Central Laboratory of the Bern University Hospital. Kidney stone composition analysis was performed at the Central Laboratory of the Bern University Hospital by Fourier transform infrared spectroscopy [22].

Inclusion criteria for NKSF were i) written informed consent, ii) age ≥ 18 years, and iii) no history of past kidney stone episodes and no evidence of asymptomatic nephrolithiasis or nephrocalcinosis on ultrasound at the time of enrolment. All NKSF underwent a metabolic work-up that was similar to BKSR participants (Fig.1).

Whole exome sequencing and variant calling

Genomic DNA was isolated from peripheral blood leucocytes (NucleoSpin, Macherey-Nagel, Switzerland). Exomes were captured using the Agilent SureSelect Human All Exon v6-Kit (Santa Clara, CA), and high-throughput sequencing was performed on a HiSeq X-Ten platform (Illumina, San Diego, CA). Reads were aligned to the human reference genome (Genome Reference Consortium build 38 (GRCh38)/human genome 38 (hg38) with the BWA-MEM algorithm of Burrows-Wheeler Aligner 0.7.17-r1188 (BWA) [23]. BAM files were generated from SAM files and sorted by SAMtools 1.10 [24]. Duplicates were removed with Picard 2.20.0 (Broad Institute, Cambridge, MA). Variant calling was conducted using Genome analysis Toolkit v3.8 (Broad Institute, Cambridge, MA) to call single nucleotide variants (SNVs) and small insertions and deletions (InDels) from BAM files. The obtained VCFs were annotated using Ensembl Variant Effect Predictor Release 106 (VEP) [25]. Pooled VCF files of all patients were then imported in a dedicated MySQL-database (MariaDB 10.4), and variants were filtered for region of interest (exons and splice regions), predicted consequences (protein truncating, mRNA splicing, missense, synonymous, insertion/deletion), genome aggregation database (gnomAD) minor allele frequency (<1% in all populations) [26]. We then focused on variants in a panel of 34 genes previously implicated in monogenic kidney stone disease. The panel included the following genes: *ADCY10, AGXT, APRT, ATP6V0A4, ATP6V1B1, ATP6V1C2, CA2, CASR, CLCN5, CLCNKB, CLDN16, CLDN19, CYP24A1, FAM20A, FOXI1, GRHPR, HNF4A, HOGA1, HPRT1, KCNJ1, OCRL, SLC12A1, SLC22A12, SLC26A1, SLC2A9, SLC34A1, SLC34A3, SLC3A1, SLC4A1, SLC7A9, SLC9A3R1, VDR, WDR72* and *XDH* [10,13-15] (Figure 1, lower panel). Subsequently, further variant stratification was performed according to the diagnostic criteria of the American College of Medical Genetics and Genomics (ACMG)[27] after manual review of phenotype data. Only variants classified as likely pathogenic (LP) or pathogenic (P) applying the ACMG criteria were defined as diagnostic variants leading to a molecular genetic diagnosis (Supplemental Fig. 1).

Statistical Analysis

Continuous variables were reported as medians with 25th-75th percentiles or means with standard deviations and categorical variables were reported as counts with percentages, as appropriate. Different statistical methods were employed to analyze differences between independent groups, depending on the nature of the variables involved. The Mann-Whitney U test was used for non-normally distributed continuous variables, while the Student's t-test was applied for those that were normally distributed. For categorical variables, the Fisher's Exact Test was implemented. Findings from these analyses have been summarized and presented in the form of descriptive tables. Statistical tests were two-sided and a *p*-value < 0.05 was considered statistically significant. Statistical analyses were performed using the software Stata, version 16 (Statacorp, TX, USA). Pie-charts and dot plots were generated with GraphPad Prism, version 8.4.3 (GraphPad Software, San Diego, CA, USA).

RESULTS:

Study cohort

We performed WES in a total of 901 individuals, including 787 KSF and 114 NKSF (Fig. 1). Clinical characteristics of the study cohort, separated in KSF and NKSF, are shown in Table 1. Mean age ± standard deviation (SD) was 46.6±14.5 years in KSF and 42.4±14.9 years in NKSF, respectively. The majority of KSF were male (71.8 %, N=565), whereas the percentage of men was lower in NKSF (54 %, N=61). KSF were significantly more likely to report a positive family history of kidney stones compared to NKSF (43.6 % vs. 6.8 %, Table 1).

Genetic analysis

Among 787 unrelated, unselected adult KSF, we discovered in 66 patients (8.4 %) pathogenic or likely pathogenic variants in genes associated with nephrolithiasis and respecting the relevant mode of inheritance (autosomal dominant and/or autosomal recessive and X-linked recessive) (Table 4, Fig. 1, Fig. 2). Diagnostic variants were detected in 14 of 34 analyzed genes (n= number of patients with diagnostic variants/molecular genetic diagnosis): *ADCY10* (n=1), *AGXT (n=1), ATP6V1B1 (n=1), CASR* (n=4), *CLDN16* (n=8), *CYP24A1* (n=13), *GRHPR (n=1), HOGA1 (n=1), SLC3A1 (n=9), SLC4A1* (n=1), *SLC7A9 (n=7), SLC12A1 (n=1), SLC34A1 (n=2), SLC34A3 (n=17).* Of the diagnostic variants, 18 % (12/66) were novel and had not been previously reported in ClinVar or HGMD©. We identified monoallelic diagnostic variants in eight genes previously associated with autosomal dominant nephrolithiasis (*ADCY10, CASR, CLDN16, CYP24A1, SLC4A1, SLC7A9, SLC34A1, SLC34A3*), and biallelic diagnostic variants in 8 genes associated with autosomal recessive nephrolithiasis (*AGXT, ATP6V1B1, CYP24A1, GRHPR, HOGA1, SLC3A1, SLC7A9, SLC12A1*). One of the 66 patients with a molecular genetic diagnosis had digenic disease with biallelic *CYP24A1* variants and a monoallelic *CLDN16* variant. Diagnostic yield was similar between first-time and recurrent

stone formers (Supplementary Table 1), and between men and women (Table 2, Supplementary Table 2).

Genotype-phenotype correlations

Mean age of first kidney stone event (30.5±13.7 years vs. 35.9±13.8 years, p=0.004) and mean age of presentation for metabolic-work up (42±16 years vs. 47.2±14.4 years, p<0.001) were lower in KSF with molecular genetic diagnosis compared to KSF without molecular genetic diagnosis (Table 2). Furthermore, cystine stones were significantly more common (23.4 % vs. 1.4 %) and calcium oxalate monohydrates stones less common (31.9 % vs. 52.5 %) in KSF with a molecular genetic diagnosis compared to KSF without molecular genetic diagnosis, in line with higher urinary cystine and urine pH in KSF with a molecular genetic diagnosis (Supplemental Fig. 2). The prevalence of a positive family history of kidney stone disease was similar in both groups (43.4 % vs. 46.0 %). Compared to KSF with monoallelic diagnostic variants, KSF with biallelic diagnostic variants were younger at the first kidney stone episode (23.6±13 years vs. 33.7±13 years, p=0.007), had more past kidney stone events [5 (2, 5) vs. 3 (2,4), p=0.028], and were more likely to have cystine stones (69 % vs. 0 %) (Table 3), with subsequent differences in urine volume, urine pH and urinary cystine (Supplemental Fig. 3). Prior to WES, a monogenic kidney stone disease was known or suspected in only 18 of the 66 individuals (27 %) with a final molecular genetic diagnosis, despite each case being reviewed by a kidney stone expert. In 48 of 66 individuals (73 %) genetic analysis established a new or corrected a suspected *a priori* diagnosis.

The most common molecular genetic diagnosis in our cohort was cystinuria (n=16) due to diagnostic variants in *SLC3A1* (type A cystinuria, n=9), *SLC7A9* (type B cystinuria, n=7). Urine cystine excretion was increased in all KSF with the genetic diagnosis of cystinuria, except in one patient for which no urine cystine quantification was available and in patient # 5678 with a monoallelic pathogenic *SLC7A9* variant. Absolute urine cystine excretion was similar in KSF

with biallelic *SLC3A1* and *SLC7A9* variants, but significantly lower in patients with monoallelic *SLC7A9* variants (Supplemental Fig. 4). KSF with biallelic *SLC3A1* or *SLC7A9* variants all had cystine stones, whereas the three KSF with monoallelic *SLC7A9* variants presented with calcium-containing kidney stones without any cystine content. Age of first stone event was similar in KSF with biallelic *SLC3A1* and *SLC7A9* variants, with a nonsignificant trend to later onset in patients with monoallelic *SLC7A9* variants (Supplemental Fig. 4). Number of stone events was not significantly different comparing KSF with monoallelic and biallelic molecular cystinuria diagnosis. In seven individuals with cystine-containing kidney stones and in two individuals with increased urinary cysteine (but without signs of generalized proximal tubular dysfunction) in our cohort of 787 KSF, no diagnostic variants in *SLC3A1* or *SLC7A9* could be identified (Supplemental Table 3).

The second most common molecular genetic diagnosis was renal phosphate wasting due to heterozygous variants in the genes encoding renal sodium/phosphate co-transporters NaPi-2a and Napi-2c, *SLC34A1 (n=2)* and *SLC34A3 (n=18)*, respectively. Patients with monoallelic *SLC34A1* variants displayed normal plasma phosphate but hypercalciuria, hypocitraturia, CaP stones, nephrocalcinosis and chronic kidney disease (CKD). We found no evidence for a generalized proximal tubular dysfunction (Fanconi syndrome) in these patients. In contrast, KSF with monoallelic *SLC34A3* variants presented with normal phosphate, hypercalciuria and CaOx stones but without nephrocalcinosis or CKD.

A total of 13 patients had diagnostic variants in *CYP24A1,* which encodes the Vitamin-D inactivating enzyme Vitamin D-24 hydroxylase. Of these, five patients carried biallelic and eight monoallelic variants. Both groups of patients had hypercalciuria, but hypercalcemia and/or a suppressed parathyroid hormone (PTH) and nephrocalcinosis was only present in patients with biallelic disease. Hypercalciuria was more pronounced in patients with biallelic variants, while patients with monoallelic variants presented with higher stone number

(Supplemental Fig. 4). Of interest, all patients with biallelic variants in *CYP24A1*, but no patient with a monoallelic *CYP24A1* variant, displayed cystic kidney disease. Common misdiagnoses were polycystic kidney disease or medullary sponge kidney. Two patients with biallelic *CYP24A1* variants underwent parathyroidectomy for a suspicion of primary hyperparathyroidism (PHPT), without phenotype alleviation postoperatively.

We identified eight patients in our cohort carrying the same previously described monoallelic variant (c.458A>G, p.Asn153Ser) in *CLDN16*, encoding the tight junction protein claudin-16 (also known as paracellin-1) [28]. These patients presented with hypercalciuria and calcium oxalate stones but all had normal renal function and normal plasma magnesium. One patient (#5334) had a digenic disease with biallelic *CYP24A1* variants and a monoallelic *CLDN16* variant. He displayed severe hypercalciuria with early onset nephrolithiasis, a suppressed PTH, osteopenia and multiple kidney cysts.

Two patients in our cohort had inherited distal renal tubular acidosis. The diagnosis was already established in one patient carrying a homozygous pathogenic variant in *ATP6V1B1*. He presented with severe normal anion gap metabolic acidosis, medullary nephrocalcinosis, recurrent carbonate apatite stones and sensorineural deafness. The second patient carried a hitherto unknown heterozygous pathogenic variant in *SLC4A1* and presented with normal blood pH and bicarbonate, pronounced hypocitraturia and a normal to mildly alkaline urine pH. He was also known for a longstanding type 2 diabetes mellitus and found to have concomitant hyperoxaluria.

We identified three patients with primary hyperoxaluria in our cohort. The diagnosis was already established in the patient with primary hyperoxaluria type 1 (PH1) due to a homozygous pathogenic *AGXT* variant and in the patient with primary hyperoxaluria type 2 (PH2) due to a homozygous pathogenic *GRHPR* variant. Both patients suffered from recurrent calcium oxalate monohydrate stones. The PH1 patient had his first kidney stone episode before 5 years of age,

but continues to have normal kidney function in his late 30s. The PH2 patient had his first kidney stone episode in his late 20s but then developed progressive CKD and had to start dialysis in his late 50s. For the patient with primary hyperoxaluria type 3 (PH3) due to a homozygous pathogenic *HOGA1* variant, the diagnosis of PHO was previously unknown. The first kidney stone episode was in his 30s. At the time of the metabolic work-up in his late 60s, he had CKD stage 2 and a urine oxalate in the upper normal range on free-choice diet, but a strong increase of urine oxalate after a one week of a diet low in calcium and sodium.

We also identified one patient with a previously reported heterozygous diagnostic variant in *ADCY10*, the gene encoding soluble adenylate cyclase 10, which has been associated with absorptive hypercalciuria [29,30]. This patient had his first stone event at age 20, yet the only available stone analysis in the patients 60s revealed a pure uric acid stone. He was known for longstanding type 2 diabetes mellitus, and metabolic work-up in his 60s revealed mild hypercalciuria and a very low 24-h urine pH of 4.8. Finally, we identified four patients with heterozygous, likely pathogenic variants in the gene encoding the calcium-sensing receptor *CASR*, which can be associated with familial hypocalciuric hypercalcaemia type 1 (FHH1), or autosomal dominant hypocalcemia. The phenotype of these patients was very variable: two patients presented with hypercalciuria but normal plasma calcium, phosphate and PTH. One patient had hypercalcemia with a PTH in the low-normal range and low urine calcium, and one patient presented with elevated PTH, hypercalcemia, pronounced hypophosphatemia, hypercalciuria and calcium oxalate dihydrate stones, compatible with the diagnosis of PHPT. He underwent parathyroidectomy with complete normalization of the phenotype.

In the 114 NKSF included in this study, exome sequencing revealed a diagnostic variant in one individual, corresponding to a diagnostic yield of 0.9 % (Fig. 1, Fig. 2). Individual #5948 was found to carry a heterozygous *SLC34A3* variant (Table 4) and displayed a normal plasma phosphate and calcium, but an elevated $1,25\text{-}(OH)_2$ vitamin D, as well as hypercalciuria.

DISCUSSION

In this exome-sequencing study in a large, unselected European cohort of 787 adult KSF, we detected diagnostic variants in 34 kidney stone disease associated genes in 66 patients (8.4 %). This diagnostic yield is lower compared to most previous studies with selected groups of kidney stone formers [10,13,31]. Yet it is substantial, especially when considering the broad inclusion criteria, the high prevalence of the disease and the potential rate of false-negatives due to stringent molecular genetic diagnosis criteria and technical limitations of exome sequencing such as inability to detect deep intronic or difficulty in reliably calling copy-number variants. Furthermore, there are numerous variants of unknown significance (VUS), which could be hereafter classified as likely pathogenic or pathogenic. In fact, the diagnostic yield observed is comparable to neurometabolic disorders or cancer, for which exome sequencing is now routinely used [11,32,33]. Interestingly, the diagnostic yield was not different between first time and recurrent stone formers (Suppl. Table 1). Similarly, no difference in the diagnostic yield was detected when stratified by sex (Table 2, Suppl. Table 2). Thus, our results indicate that a significant fraction of adults with idiopathic kidney stones actually have an underlying monogenic disease that was missed prior to genetic testing.

Molecular genetic diagnoses were most frequent for disorders of renal phosphate wasting (*SLC34A1*, *SLC34A3*), calcium-metabolism (*CYP24A1*, *CLDN16*), and cystinuria (*SLC3A1*, *SLC7A9*) (Figure 2, D). The majority of patients (68 %) with a genetic diagnosis in our cohort had monoallelic disease (Figure 2, C). Phenotypes of these patients were often discrete and variable, and there was a large phenotype overlap between individuals with and without a genetic diagnosis. Yet, the low prevalence of diagnostic variants detected in NKSF suggests a high penetrance of nephrolithiasis gene variants in adults.

KSF with diagnostic monoallelic variants in *SLC34A1* and *SLC34A3* had both hypercalciuria but otherwise distinct clinical features: KSF with *SLC34A1* variants had CaP stones,

nephrocalcinosis and CKD, whereas KSF with *SLC34A3* variants presented with CaOx stones but without structural or functional kidney abnormalities. Our study adds additional phenotypic information on the role of monoallelic *SLC34A3* variants as a frequent contributor to kidney stone disease [34]. The phenotype of KSF with monoallelic *SLC34A3* variants was very similar to KSF with monoallelic variants in *CYP24A1* or *CLDN16*. In addition to hypercalciuria and calcium oxalate stones, KSF with biallelic *CYP24A1* variants also displayed hypercalcemia and/or a suppressed PTH and kidney cysts, as reported previously [35,36].

Biallelic pathogenic variants in *CLDN16* cause autosomal-recessive familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), characterized by marked hypomagnesemia, hypercalciuria, recurrent nephrolithiasis, nephrocalcinosis and progressive kidney failure [28]. An increased prevalence of nephrolithiasis has been reported previously in heterozygous carriers of pathogenic *CLDN16* variants [37,38]. The phenotype of KSF in our cohort with the monoallelic *CLDN16* variant was subtle and included hypercalciuria with recurrent calcium oxalate stones but normal plasma magnesium and no evidence of CKD. Our study reveals that 12 % (8 of 67) of patients with a genetic diagnosis had a diagnostic *CLDN16* variant, indicating that *CLDN16*-associated disease is an important cause of monogenic nephrolithiasis in adults.

In line with previous reports [29,39,40], we observed that patients with diagnostic monoallelic *SLC7A9* variants presented with calcium-containing kidney stones, consonant with the concept that cystine promotes growth and aggregation of calcium oxalate crystals in the urine [41]. In contrast, all patients with biallelic disease had cystine stones. The reason for this clear separation in stone types remains unclear, but may be a result of differences in urinary cystine excretion, as patients with monoallelic *SLC7A9* variants presented with significantly lower levels of urinary cystine than patients with biallelic *SLC7A9* or *SLC3A1* variants (Supplemental Fig. 4). We also confirmed a high prevalence of CKD in patients with cystinuria [42]. Interestingly, however, this seemed to apply only to patients with cystinuria due to biallelic

disease. Another important finding of our study was the fact that we were unable to provide a genetic diagnosis in 9 individuals with cystine-containing kidney stones (n=7) or increased urinary excretion of dibasic amino acids (n=2) (Supplemental Table 3). While this could be explained at least in part by technical issues (intronic variants or larger CNVs missed by exome sequencing), likely additional, yet to be discovered genes, are associated with the clinical phenotype of cystinuria.

Concerning monoallelic variants in *SLC7A9*, the variant c.544G>A / p.(Ala182Thr) in *SLC7A9*, described as being associated with autosomal dominant cystinuria, was found in four stone formers (0.507%), whereas one individual had an additional homozygous pathogenic variant in *SLC3A1* (#5479), indicating that the *SLC7A9* c.544G>A variant was not enriched in the cohort (gnomAD frequency: 0.61%). Furthermore, the three patients carrying only the *SLC7A9* c.544G>A variant did not show increased urinary cystine, suggesting that the residual transport activity in these three patients is still sufficient and does not result in a cystinuria phenotype. Heterozygosity for the c.544G>A variant was demonstrated to have incomplete penetrance for cystinuria [43,44], likely due to significant residual transport activity of the variant [45,46]. Given the lack of increased urine cystine in the three patients, they were not considered as having a molecular genetic diagnosis and thus omitted from the table of solved patients.

We identified as single patient with a pathogenic heterozygous variant in *ADCY10*. While this patient had mild hypercalciuria and kidney stones since the age of 20 years, the only stone analysis performed when the patient was in his 60s revealed a pure uric acid stone. Possibly the patient had calcium-containing kidney stones due to hypercalciuria at young age and only started to develop uric acid stones when metabolic syndrome with low urine pH developed in older age. Clearly, these findings will not settle the controversy of *ADCY10* as a causal gene for nephrolithiasis [29,30]. However, our study demonstrates that pathogenic *ADCY10* variants are not common in adult KSFs. Further, we identified four patients with diagnostic *CASR* variants

in our cohort that displayed variable phenotypes. Atypical characteristics such as chondrocalcinosis or kidney stones have been described in patients with FHH1 but complicate the separation from primary hyperparathyroidism (PHPT) [47-49]. Yet, separation is of critical importance: parathyroidectomy is considered as a first-line treatment in PHPT but surgery is ineffective in FHH1. However, additional complexity arises from the fact that PHPT and FHH1 can co-exist, as observed in one of our patients (# 6023) [50,51].

Genetic diagnoses in KSF have important prognostic implications and therapeutic consequences. In several cases, however, the pathophysiology is well delineated but the effectiveness of therapeutic interventions has not been studied prospectively (e.g., *CYP24A1*-associated disease, *SLC34A1/A3*-associated disease, *CLDN16*-associated disease). The widespread use of genetic testing will facilitate the inclusion of KSF with molecular genetic diagnoses in registries and clinical trials to study disease evolution and evaluate therapeutic interventions. Currently, KSF are subjected to genetic testing if a specific disease is suspected. While clinical signs suggesting an inherited disorder have been proposed [52], monogenic disease was missed in most patients in our cohort, despite individual review of each case by a kidney stone expert. In fact, our study demonstrates that the phenotype of KSF with monogenic disease is variable and frequently subtle. In addition, there is a large phenotype overlap between KSF with and without a genetic diagnosis, precluding the definition of clear phenotypic criteria to prioritize genetic testing in adult kidney stone formers. Hence, the usefulness of clinical parameters for the prediction of monogenic disease seems to be limited in adult KSF.

Strengths of our study include the lack of patient pre-selection with broad inclusion criteria, the large sample size, availability of an ethnically-matched non-stone forming control population, a detailed phenotype, as well as the strict genetic definition of diagnostic variants and focus on established nephrolithiasis genes only. Our study also has limitations, such as the inability to

detect deep intronic and copy-number variants with exome sequencing, lack of family recruitment to perform segregation analyses, overrepresentation of men and a limited ethnic diversity.

In conclusion, our study reveals that monogenic disease is prevalent in unselected adult kidney stone formers and highlights the potential of genetic testing to direct patients to targeted therapies and clinical trials.

Author contributions

DGF, AS and JAS conceptualized the study. DGF and MAA acquired financial support. MAA, EGO and DGF designed data analysis plans. MAA, EGO and MB performed data analysis. MAA, EGO, MB, AS and DGF performed data analysis and data interpretation. MAA wrote the first draft of the manuscript. All authors contributed to discussion and editing of text and approved the final version of the manuscript.

DATA SHARING STATEMENT

The data supporting the findings of this study are available from the corresponding author upon request.

DISCLOSURE STATEMENT

The authors declare no competing interests.

DATA PRIVACY PROTECTION STATEMENT

Any participant identifiers (PIDs) included were solely used for the BKSR and not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group. Therefore, they cannot be used to identify individuals.

SUPPLEMENTARY MATERIAL

Figure S1: Stratification pathway used for whole exome sequencing (WES) data in the Bern Kidney Stone Registry (BKSR)

Figure S2: 24h urinary risk factors stratified by WES results.

Figure S3. Characteristics of stone formation stratified by zygosity

Figure S4. Genotype–phenotype correlations.

Table S1. Characteristics of stone formers stratified by stone events number

Table S2. Characteristics of stone formers with diagnostic variants stratified by sex

Table S3. Patients with cystine stones, clinical cystinuria or elevated urinary cystine but without diagnostic variants in cystinuria genes (*SLC3A1/SLC7A9*)

REFERENCES

1. Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United States from 2007 to 2016. *Urolithiasis.* 2021;49(1):27-39.
2. Ferraro PM, Curhan GC, D'Addessi A, Gambaro G. Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. *J Nephrol.* 2017;30(2):227-233.
3. New F, Somani BK. A Complete World Literature Review of Quality of Life (QOL) in Patients with Kidney Stone Disease (KSD). *Curr Urol Rep.* 2016;17(12):88.
4. Saigal CS, Joyce G, Timilsina AR. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? *Kidney Int.* 2005;68(4):1808-1814.
5. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. *The Journal of urology.* 2014;192(2):316-324.
6. Dhayat NA, Bonny O, Roth B, et al. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence. *N Engl J Med.* 2023;388(9):781-791.
7. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. *J Am Soc Nephrol.* 1997;8(10):1568-1573.
8. Goldfarb DS, Fischer ME, Keich Y, Goldberg J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. *Kidney Int.* 2005;67(3):1053-1061.
9. Edvardsson VO, Palsson R, Indridason OS, Thorvaldsson S, Stefansson K. Familiality of kidney stone disease in Iceland. *Scand J Urol Nephrol.* 2009;43(5):420-424.
10. Halbritter J, Baum M, Hynes AM, et al. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. *J Am Soc Nephrol.* 2015;26(3):543-551.
11. Tarailo-Graovac M, Shyr C, Ross CJ, et al. Exome Sequencing and the Management of Neurometabolic Disorders. *N Engl J Med.* 2016;374(23):2246-2255.
12. Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic Utility of Exome Sequencing for Kidney Disease. *N Engl J Med.* 2019;380(2):142-151.
13. Daga A, Majmundar AJ, Braun DA, et al. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. *Kidney Int.* 2018;93(1):204-213.
14. Braun DA, Lawson JA, Gee HY, et al. Prevalence of Monogenic Causes in Pediatric Patients with Nephrolithiasis or Nephrocalcinosis. *Clin J Am Soc Nephrol.* 2016;11(4):664-672.
15. Amar A, Majmundar AJ, Ullah I, et al. Gene panel sequencing identifies a likely monogenic cause in 7% of 235 Pakistani families with nephrolithiasis. *Hum Genet.* 2019;138(3):211-219.
16. Dhayat NA, Schaller A, Albano G, et al. The Vacuolar H+-ATPase B1 Subunit Polymorphism p.E161K Associates with Impaired Urinary Acidification in Recurrent Stone Formers. *J Am Soc Nephrol.* 2016;27(5):1544-1554.
17. Dhayat NA, Luthi D, Schneider L, Mattmann C, Vogt B, Fuster DG. Distinct phenotype of kidney stone formers with renal phosphate leak. *Nephrol Dial Transplant.* 2019;34(1):129-137.
18. Dhayat NA, Schneider L, Popp AW, et al. Predictors of Bone Mineral Density in Kidney Stone Formers. *Kidney Int Rep.* 2022;7(3):558-567.
19. Fuster DG, Morard GA, Schneider L, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. *Nephrol Dial Transplant.* 2022;37(2):335-348.

20. Pak CY, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. *Am J Med.* 1980;69(1):19-30.
21. Pak CY, Kaplan R, Bone H, Townsend J, Waters O. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. *N Engl J Med.* 1975;292(10):497-500.
22. Cloutier J, Villa L, Traxer O, Daudon M. Kidney stone analysis: "Give me your stone, I will tell you who you are!". *World J Urol.* 2015;33(2):157-169.
23. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* 2009;25(14):1754-1760.
24. Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools. *Gigascience.* 2021;10(2).
25. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. *Genome Biol.* 2016;17(1):122.
26. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature.* 2020;581(7809):434-443.
27. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405-424.
28. Simon DB, Lu Y, Choate KA, et al. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. *Science.* 1999;285(5424):103-106.
29. Halbritter J, Baum M, Hynes AM, et al. Fourteen Monogenic Genes Account for 15% of Nephrolithiasis/Nephrocalcinosis. *J Am Soc Nephrol.* 2014.
30. Reed BY, Gitomer WL, Heller HJ, et al. Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. *J Clin Endocrinol Metab.* 2002;87(4):1476-1485.
31. Schonauer R, Scherer L, Nemitz-Kliemchen M, et al. Systematic assessment of monogenic etiology in adult-onset kidney stone formers undergoing urological intervention-evidence for genetic pretest probability. *Am J Med Genet C Semin Med Genet.* 2022;190(3):279-288.
32. Huang KL, Mashl RJ, Wu Y, et al. Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell.* 2018;173(2):355-370 e314.
33. Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. *N Engl J Med.* 2015;373(24):2336-2346.
34. Sadeghi-Alavijeh O, Chan MMY, Moochhala SH, et al. Rare variants in in the sodium-dependent phosphate transporter gene SLC34A3 explain missing heritability of urinary stone disease. *Kidney International.* 2023.
35. Tebben PJ, Milliner DS, Horst RL, et al. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. *J Clin Endocrinol Metab.* 2012;97(3):E423-427.
36. Hanna C, Potretzke TA, Cogal AG, et al. High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency. *Kidney Int Rep.* 2021;6(7):1895-1903.
37. Praga M, Vara J, Gonzalez-Parra E, et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *Kidney Int.* 1995;47(5):1419-1425.
38. Weber S, Schneider L, Peters M, et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc Nephrol.* 2001;12(9):1872-1881.
39. Elkoushy MA, Andonian S. Characterization of patients with heterozygous cystinuria. *Urology.* 2012;80(4):795-799.

40. Cupisti A, Farnesi I, Armillotta N, Francesca F. Staghorn cystine stone in a 72-year-old recurrent calcium stone former. *Clin Nephrol.* 2012;78(1):76-80.

41. Martins MC, Meyers AA, Whalley NA, Rodgers AL. Cystine: a promoter of the growth and aggregation of calcium oxalate crystals in normal undiluted human urine. *J Urol.* 2002;167(1):317-321.

42. Prot-Bertoye C, Lebbah S, Daudon M, et al. CKD and Its Risk Factors among Patients with Cystinuria. *Clin J Am Soc Nephrol.* 2015;10(5):842-851.

43. Font-Llitjos M, Jimenez-Vidal M, Bisceglia L, et al. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. *J Med Genet.* 2005;42(1):58-68.

44. Gaildrat P, Lebbah S, Tebani A, et al. Clinical and molecular characterization of cystinuria in a French cohort: relevance of assessing large-scale rearrangements and splicing variants. *Mol Genet Genomic Med.* 2017;5(4):373-389.

45. Font MA, Feliubadalo L, Estivill X, et al. Functional analysis of mutations in SLC7A9, and genotype-phenotype correlation in non-Type I cystinuria. *Hum Mol Genet.* 2001;10(4):305-316.

46. Reig N, Chillaron J, Bartoccioni P, et al. The light subunit of system b(o,+) is fully functional in the absence of the heavy subunit. *EMBO J.* 2002;21(18):4906-4914.

47. Mouly C, Vargas-Poussou R, Lienhardt A, et al. Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients. *Clin Endocrinol (Oxf).* 2020;93(3):248-260.

48. Volpe A, Guerriero A, Marchetta A, Caramaschi P, Furlani L. Familial hypocalciuric hypercalcemia revealed by chondrocalcinosis. *Joint Bone Spine.* 2009;76(6):708-710.

49. Stratta P, Merlotti G, Musetti C, et al. Calcium-sensing-related gene mutations in hypercalcaemic hypocalciuric patients as differential diagnosis from primary hyperparathyroidism: detection of two novel inactivating mutations in an Italian population. *Nephrol Dial Transplant.* 2014;29(10):1902-1909.

50. Eldeiry LS, Ruan DT, Brown EM, Gaglia JL, Garber JR. Primary hyperparathyroidism and familial hypocalciuric hypercalcemia: relationships and clinical implications. *Endocr Pract.* 2012;18(3):412-417.

51. Egan AM, Ryan J, Aziz MA, O'Dwyer TP, Byrne MM. Primary hyperparathyroidism in a patient with familial hypocalciuric hypercalcaemia due to a novel mutation in the calcium-sensing receptor gene. *J Bone Miner Metab.* 2013;31(4):477-480.

52. Ferraro PM, D'Addessi A, Gambaro G. When to suspect a genetic disorder in a patient with renal stones, and why. *Nephrol Dial Transplant.* 2013;28(4):811-820.

ACKNOWLEDGEMENTS

MAA was supported by a grant for protected research time by the InselGruppe. EGO was supported by Postdoc MobilityStipendien of the Swiss National Science Foundation (grants # P2ZHP3_195181 and P500PB_206851), and Kidney Research UK ((grants # Paed_RP_001_20180925). DGF was supported by the Swiss National Science Foundation (grants # 31003A_172974 and 33IC30_166785/1) and the Swiss National Centre of Competence in Research Kidney.CH. JAS is supported by the Northern Counties Kidney Research Fund (22/01), Kidney Research UK (Paed_RP_001_20180925), LifeArc, and the Medical Research Council (MR/Y007808/1). We thank Hans Anderegg for technical expertise in database development.

Table 1 | Characteristics of the study cohort. Characteristics are indicated separately for participants with and without kidney stone disease. Categorical variables are described by number of participants N (%), continuous variables are described by their mean (SD) or median (25th-75th percentile). eGFR, estimated glomerular filtration rate; BSA, body surface area; PTH, parathyroid hormone; SD, standard deviation.
* The Non kidney stone former (NKSF) with a diagnostic variant (#5948) has been removed for phenotypic analyses.

Characteristics	Kidney stone formers (N=787)	Non kidney stone formers (N=113) *	*p*-values
Age, years	46.64 (14.57)	42.41 (14.88)	0.007
Males	565 (71.8%)	61 (54.0%)	<0.001
Body mass index, kg/m^2	26.83 (5.08)	26.34 (4.55)	0.37
Hypertension	255 (36.0%)	28 (35.9%)	1.00
Diabetes	24 (3.1%)	1 (1.1%)	0.50
Obesity, BMI > 30 kg/m^2	168 (22.4%)	14 (15.1%)	0.11
Hyperuricemia	346 (44.0%)	54 (47.8%)	0.48
Family history of kidney stone disease	317 (43.6%)	3 (6.8%)	<0.001
Kidney stone recurrence, > 1 stone event	614 (82.2%)		
Age at first stone event, years	35.41 (13.85)		
Total number of stone events	3.00 (2.00, 4.00)		
Blood parameters			
Total calcium, mmol/L	2.36 (0.12)	2.30 (0.12)	<0.001
Ionized calcium, mmol/L	1.21 (1.19, 1.23)	1.19 (1.18, 1.22)	0.002
Phosphorus, mmol/L	1.01 (0.17)	1.01 (0.16)	0.89
Magnesium, mmol/L	0.83 (0.07)	0.86 (0.08)	<0.001
Uric acid, umol/L	328.96 (169.56)	308.44 (71.51)	0.26
Intact PTH, ng/L	39.06 (30.00, 51.00)	37.50 (30.50, 48.00)	0.56
25-OH Vitamin D$_3$, nmol/L	40.18 (27.00, 59.00)	48.50 (32.72, 72.44)	0.017
eGFR creatinine Equation CKD-EPI 2009, mL/min per 1.73 m2 BSA	94.18 (21.08)	96.31 (21.88)	0.36
Urine parameters			
Total urine volume, L/24h	1.98 (1.47, 2.54)	2.10 (1.49, 2.65)	0.41
Urine pH	5.94 (5.39, 6.60)	6.00 (5.50, 6.75)	0.14
Urine sodium / creatinine ratio, mmol/mmol/24h	13.62 (10.97, 16.98)	13.76 (9.92, 16.21)	0.37
Urine potassium / creatinine ratio, mmol/mmol/24h	4.70 (3.77, 5.82)	5.56 (4.43, 6.55)	<0.001
Urine uric acid / creatinine ratio, mmol/mmol/24h	0.61 (0.10)	0.38 (0.27)	<0.001
Urine calcium / creatinine ratio, mmol/mmol/24h	0.43 (0.30, 0.58)	0.33 (0.21, 0.44)	<0.001
Urine magnesium / creatinine ratio, mmol/mmol/24h	0.30 (0.24, 0.38)	0.32 (0.27, 0.42)	0.059
Urine citrate / creatinine ratio, mmol/mmol/24h	0.19 (0.13, 0.27)	0.24 (0.18, 0.30)	0.003
Urine phosphate / creatinine ratio, mmol/mmol/24h	2.18 (0.54)	2.24 (0.57)	0.41
Urine oxalate / creatinine ratio, mmol/mmol/24h	0.03 (0.02, 0.04)	0.03 (0.02, 0.05)	0.062
Stone phenotypes			
Calcium oxalate dihydrate	73 (12.9%)		
Calcium oxalate monohydrate	287 (50.8%)		
Calcium phosphate	130 (23.0%)		
Uric acid	38 (6.7%)		
Cystine	18 (3.2%)		
Struvite	15 (2.7%)		

Table 2 | Characteristics of stone formers with and without pathogenic gene variants. Characteristics are indicated separately for stone formers with and without P, LP, gene variants. Categorical variables are described by number of participants N (%), continuous variables are described by their mean (SD) or median (25th-75th percentile). eGFR, estimated glomerular filtration rate; BSA, body surface area; PTH, parathyroid hormone; SD, standard deviation.

Characteristics	No pathogenic gene variants (N=721)	P or LP variants (N=66)	*p*-values
Age, years	47.16 (14.38)	40.92 (15.54)	<0.001
Males	515 (71.4%)	50 (75.8%)	0.57
Body mass index, kg/m^2	26.94 (5.15)	25.65 (4.06)	0.054
Hypertension	232 (35.9%)	23 (37.7%)	0.78
Diabetes	23 (3.3%)	1 (1.5%)	0.71
Obesity, BMI > 30 kg/m^2	158 (23.0%)	10 (15.9%)	0.21
Hyperuricemia	312 (43.3%)	34 (51.5%)	0.20
Family history of kidney stone disease	288 (43.4%)	29 (46.0%)	0.69
Kidney stone recurrence, > 1 stone event	561 (82.1%)	53 (82.8%)	1.00
Age at first stone event, years	35.86 (13.79)	30.47 (13.72)	0.004
Total number of stone events	3.00 (2.00, 4.00)	3.00 (2.00, 4.50)	0.40
Blood parameters			
Total calcium, mmol/L	2.35 (0.12)	2.39 (0.12)	0.008
Ionized calcium, mmol/L	1.21 (1.19, 1.23)	1.22 (1.21, 1.25)	0.011
Phosphorus, mmol/L	1.01 (0.17)	1.00 (0.15)	0.59
Magnesium, mmol/L	0.83 (0.07)	0.82 (0.07)	0.47
Uric acid, umol/L	327.64 (175.63)	343.77 (71.88)	0.47
Intact PTH, ng/L	40.00 (30.45, 52.00)	33.50 (24.00, 46.00)	0.009
25-OH Vitamin D$_3$, nmol/L	40.00 (27.00, 59.00)	43.00 (26.00, 58.00)	0.81
eGFR creatinine Equation CKD-EPI 2009, mL/min per 1.73 m2 BSA	96.47 (81.63, 109.12)	96.14 (80.19, 108.60)	0.82
Urine parameters			
Total urine volume, L/24h	1.96 (1.47, 2.53)	2.16 (1.46, 2.60)	0.19
Urine pH	5.92 (5.37, 6.54)	6.57 (5.63, 6.88)	<0.001
Urine sodium / creatinine ratio, mmol/mmol/24h	13.56 (10.97, 16.85)	13.97 (10.94, 18.78)	0.48
Urine potassium / creatinine ratio, mmol/mmol/24h	4.70 (3.76, 5.80)	4.93 (3.83, 6.28)	0.52
Urine uric acid / creatinine ratio, mmol/mmol/24h	0.61 (0.10)	0.60 (0.10)	0.43
Urine calcium / creatinine ratio, mmol/mmol/24h	0.43 (0.30, 0.59)	0.45 (0.33, 0.55)	0.68
Urine magnesium / creatinine ratio, mmol/mmol/24h	0.30 (0.24, 0.38)	0.30 (0.24, 0.40)	0.69
Urine citrate / creatinine ratio, mmol/mmol/24h	0.19 (0.13, 0.27)	0.19 (0.12, 0.27)	0.98
Urine phosphate / creatinine ratio, mmol/mmol/24h	2.19 (0.55)	2.12 (0.42)	0.33
Urine oxalate / creatinine ratio, mmol/mmol/24h	0.03 (0.02, 0.04)	0.03 (0.01, 0.04)	0.44
Urine cystine / creatinine ratio, mmol/mol/24h	4.00 (3.00, 5.00)	5.00 (3.00, 59.00)	<0.001
Stone phenotypes			
Calcium oxalate dihydrate	66 (12.7%)	7 (14.9%)	0.65
Calcium oxalate monohydrate	272 (52.5%)	15 (31.9%)	0.009
Calcium phosphate	120 (23.2%)	10 (21.3%)	0.86
Uric acid	37 (7.1%)	1 (2.1%)	0.35
Cystine	7 (1.4%)	11 (23.4%)	<0.001
Struvite	13 (2.5%)	2 (4.3%)	0.36

Table 3 | Characteristics of stone formers with diagnostic variants. Characteristics are indicated separately for participants with diagnostic (P or LP) gene variants, stratified by zygosity**.** Categorical variables are described by number of participants N (%), continuous variables are described by their mean (SD) or median (25th-75th percentile). eGFR, estimated glomerular filtration rate; BSA, body surface area; PTH, parathyroid hormone; SD, standard deviation.

Characteristics	Bi-allelic (N=22)	Mono-allelic (N=44)	*p*-values
Age, years	39.08 (16.22)	41.80 (15.32)	0.51
Males	13 (59%)	37 (84%)	0.035
Body mass index, kg/m^2	24.20 (3.05)	26.33 (4.31)	0.052
Hypertension	8 (38%)	15 (38%)	1.00
Diabetes	0 (0%)	1 (2%)	1.00
Obesity, BMI > 30 kg/m^2	1 (5%)	9 (21%)	0.15
Hyperuricemia	12 (55%)	22 (50%)	0.80
Family history of kidney stone disease	8 (38%)	21 (50%)	0.43
Kidney stone recurrence, > 1 stone event	17 (81%)	36 (84%)	1.00
Age at first stone event, years	23.61 (12.61)	33.73 (13.15)	0.007
Total number of stone events	5.00 (2.00, 5.00)	3.00 (2.00, 4.00)	0.028
Blood parameters			
Total calcium, mmol/L	2.39 (0.11)	2.39 (0.12)	0.99
Ionized calcium, mmol/L	1.23 (1.20, 1.26)	1.22 (1.21, 1.25)	0.98
Phosphorus, mmol/L	1.08 (0.13)	0.96 (0.14)	0.004
Magnesium, mmol/L	0.81 (0.07)	0.82 (0.08)	0.56
Uric acid, umol/L	346.00 (79.40)	342.79 (69.28)	0.87
Intact PTH, ng/L	39.00 (23.00, 56.00)	31.30 (24.00, 43.81)	0.40
25-OH Vitamin D$_3$, nmol/L	35.50 (22.00, 73.00)	43.00 (29.00, 54.00)	0.73
eGFR creatinine Equation CKD-EPI 2009, mL/min per 1.73 m2 BSA	94.01 (69.61, 98.79)	99.07 (81.03, 112.16)	0.12
Urine parameters			
Total urine volume, L/24h	2.53 (2.37, 3.43)	1.88 (1.36, 2.47)	<0.001
Urine pH	6.83 (6.63, 7.34)	6.15 (5.60, 6.67)	0.004
Urine sodium / creatinine ratio, mmol/mmol/24h	18.83 (15.36, 20.98)	12.40 (9.96, 14.85)	<0.001
Urine potassium / creatinine ratio, mmol/mmol/24h	6.54 (5.52, 7.97)	4.06 (3.34, 5.07)	<0.001
Urine uric acid / creatinine ratio, mmol/mmol/24h	0.60 (0.15)	0.60 (0.07)	0.94
Urine calcium / creatinine ratio, mmol/mmol/24h	0.38 (0.23, 0.53)	0.48 (0.36, 0.57)	0.092
Urine magnesium / creatinine ratio, mmol/mmol/24h	0.38 (0.29, 0.48)	0.27 (0.23, 0.35)	0.010
Urine citrate / creatinine ratio, mmol/mmol/24h	0.22 (0.14, 0.32)	0.18 (0.10, 0.26)	0.21
Urine phosphate / creatinine ratio, mmol/mmol/24h	2.14 (0.47)	2.11 (0.39)	0.77
Urine oxalate / creatinine ratio, mmol/mmol/24h	0.04 (0.02, 0.05)	0.02 (0.01, 0.04)	0.019
Urine cystine / creatinine ratio, mmol/mol/24h	208.00 (3.00, 268.00)	4.50 (3.00, 8.00)	0.005
Stone phenotypes			
Calcium oxalate dihydrate	0 (0%)	7 (23%)	0.078
Calcium oxalate monohydrate	3 (19%)	12 (39%)	0.20
Calcium phosphate	2 (13%)	8 (26%)	0.46
Uric acid	0 (0%)	1 (3%)	1.00
Cystine	11 (69%)	0 (0%)	<0.001
Struvite	0 (0%)	2 (6%)	0.54

Table 4 Genotype and phenotype of solved patients with molecular diagnosis. Acc.N°: RefSeq accession number, ACMG: American College of Medical Genetics, AR: autosomal recessive, AD: autosomal dominant, dbSNP: Reference SNP number of variant, het: heterozygous, hom: homozygous, , LP: likely pathogenic, P: pathogenic, Novel: mutation detected for the first time in this study/not previously described, NS: nonsense, Family history: N= no, Y=yes, , M: male, F: female, mo: months, NL: Nephrolithiasis, NC: Nephrocalcinosis, dRTA: distal renal tubular acidosis, PHPTH: primary hyperparathyroidism, CKD: chronic kidney disease. Stone analysis: CaOx: Calcium oxalate, COM: Calcium oxalate monohydrate, COD: Calcium oxalate dihydrate, CaP: Calcium phosphate, CA: Carbonate apatite, Brushite: Calcium hydrogen phosphate dihydrate, MAP: Magnesium ammonium phosphate (=Struvite), UA: Uric acid.

ID	Gene	Inheritance	Allelic state	Nucleotide change	Amino acid change	ACMG	Acc. N° dbSNP	Sex	Age at first stone (range)	Number of past stone events	Stone composition analysis (%)	Family history	Key Phenotype	Clinical diagnosis before WES	Genetic diagnosis after WES
ADCY10 – Idiopathic Hypercalciuria															
5750	*ADCY10*	AD	het	c.4477del	p.Leu1493SerfsTer24	LP	NM_018417.6 rs576118131	M	21-25	2	50 UA, 50 UA dihydrate	N	UA NL, DM II Hypercalciuria (5.3) Low urine pH (4.8)	UA NL	Absorptive hypercalciuria
AGXT – Primary Hyperoxaluria Type 1 (PH1)															
5011	*AGXT*	AR	hom	c.466G>A	p.Gly156Arg	P	NM_000030.3 rs121908530	M	0-5	8	1) 80 COM, 20 COD 2) 80 COM, 20 COD	N	CaOx NL, normal kidney function Hyperoxaluria (1100)	PH1	PH1
ATP6V1B1 – Distal renal tubular acidosis with sensorineural hearing loss/deafness (AR dRTA)															
5775	*ATP6V1B1*	AR	hom	c.242T>C	p.Leu81Pro	P	NM_001692.4 rs121964880	M	N/A	>5	100 CA	N	CaP NL, dRTA, medullary NC, sensorineural deafness	AR-dRTA	AR-dRTA
CASR –Familial hypocalciuric hypercalcemia type 1 (FHH1)															
5026	*CASR*	AD	het	c.206G>A	p.Arg69His	LP	NM_000388.4 rs193922432	F	16-20	1	N/A	N	NL (radiopaque stones) Hypercalcemia (total: 2.7; ionized 1.37) Normal plasma phosphate (0.9) Normal urine calcium (2.9) Normal PTH (19)	Idiopathic NL	FHH1
5666	*CASR*	AD	het	c.1942C>T	p.Arg648Cys	LP	NM_000388.4 rs1185593894	M	36-40	3	90 COM, 10 UA	Y	CaOx NL, osteopenia Normal plasma calcium (2.46) Hypercalciuria (9.35) Normal PTH (27)	Idiopathic NL	FHH1
5686	*CASR*	AD	het	c.269A>C	p.Asn90Thr	LP	NM_000388.4 rs193922439	M	26-30	2	1) 100 COM; 2) 60 COM, 30 COD, 10 CA	N	CaOx NL Normal plasma calcium (2.44) Hypercalciuria (5.88) Normal PTH (25)	Idiopathic NL	FHH1
6023	*CASR*	AD	het	c.848T>C	p.Ile283Thr	LP	NM_000388.4 rs142745096	M	N/A	N/A	2) 90 COD, 5 COD, 5 CA	N	CaOx NL, PHPT Hypercalcemia (total: 2.8; ionized 1.38) Hypophosphatemia (0.52)	PHPT, s/p parathyroidectomy	FHH1

													Hypercalciuria (12.2) High PTH (111)		
CYP24A1 – (Infantile) HC/NL, 1,25-OH vitamin D-24 hydroxylase deficiency															
5028	*CYP24A1*	AD/AR	het	c.428_430 del	p.Glu143del	LP	NM_000782.5 rs777676129	M	56-60	3	1): 50 COD, 25 CA, 25 MAP, 2): 90 Brushite, 10 COD	N	CaOx NL, osteopenia. Normal plasma calcium (total: 2.44; ionized 1.28) Normal PTH (37) Normal 1,25 Vit D (156) Hypercalciuria (11.35)	Idiopathic NL	(Infantile) HC/NL
5033	*CYP24A1*	AD/AR	hom	c.1186C>T	p.Arg396Trp	P	NM_000782.5 rs114368325	F	21-25	1	N/A	Y	NL, osteoporosis, single kidney cyst. Hypercalcemia (total 2.64; ionized 1.4) Normal PTH (47) Normal 25-Vit D (83) Normal 1,25-Vit D (105) Hypercalciuria (7.7)	Idiopathic, infantile HC, NL, s/p parathyreo-idectomy	(Infantile) HC/NL
5037	*CYP24A1*	AD/AR	het	c.1315C>T	p.Arg439Cys	LP	NM_000782.5 rs374292194	M	31-35	2	90 COM, 10 COD	N	CaOx NL, osteopenia Normal plasma calcium (total 2.43; ionized 1.23) Normal PTH (34) Normal 25-Vit D (35) Normal 1,25-Vit D (98) Hypercalciuria (5.8)	Idiopathic NL	(Infantile) HC/NL
5052	*CYP24A1*	AD/AR	hom	c.1186C>T	p.Arg396Trp	P	NM_000782.5 rs114368325	M	N/A	1	N/A	Y	NL, Nephrocalcinosis, multiple kidney cysts, CKD stage 4, Osteopenia, Chondrocalcinosis. Hypercalcemia (total 2.8; ionized 1.41) Low PTH (4) Low 25-Vit D (16) Normal 1,25-Vit D (112) Hypercalciuria (7.2)	Infantile HC/NL, CKD IV° due to NC, s/p parathyreo-idectomy	(Infantile) HC/NL
5152	*CYP24A1*	AD/AR	het	c.1186C>T	p.Arg396Trp	P	NM_000782.5 rs114368325	M	26-30	2	N/A	N	NL, multiple kidney cysts. Normocalcemia (total 2.4; ionized 1.26) Low PTH (10) Normal 25-Vit D (87) Normal 1,25-Vit D (177) Hypercalciuria (19)	Idiopathic NL, polycystic kidney disease	(Infantile) HC/NL
			het	c.428_430 del	p.Glu143del	LP	rs777676129								
5313	*CYP24A1*	AD/AR	het	c.1186C>T	p.Arg396Trp	P	NM_000782.5 rs114368325	M	N/A	4	80 COM, 20 COD	Y	CaOx NL, osteopenia Normal plasma calcium (total 2.46; ionized 1.25) Normal PTH (28) Low 25-Vit D (30)	Idiopathic NL	(Infantile) HC/NL

ID	Gene	Inheritance	Zygosity	cDNA	Protein	Class	Transcript/rs	Sex	Age	Stones	Stone composition	Recurrent	Clinical/Biochemical	Diagnosis	Differential
												Normal 1,25-Vit D (153) Normal urine calcium (2.4)		
5334	*CYP24A1*	AD/AR	het	c.1226T>C	p.Leu409Ser	LP	NM_000782.5 rs6068812	M	21-25	3	1) 90 COM, 10 COD; 2) 80 COM, 20 COD	Y	CaOx NL, osteopenia, multiple kidney cysts. Normal plasma calcium (total 2.48; ionized 1.27) Normal plasma magnesium (0.72) Low PTH (9) Normal 25-Vit D (59) Normal 1,25-Vit D (93) Hypercalciuria (14.3)	Idiopathic NL, polycystic kidney disease	(Infantile) HC/NL
			het	c.400T>G	p.Trp134Gly	LP	rs1170841548								
5334	*CLDN16*	AD/AR	het	c.458A>G	p.Asn153Ser	LP	NM_006580.4 rs201367228								FHHNC
5377	*CYP24A1*	AD/AR	het	c.1226T>C	p.Leu409Ser	LP	NM_000782.5 rs6068812	M	36-40	5	1) 95 COM/COD, 5 CA 2) 20 COM, 80 UA 2) 20 COD, 80 UA	N	CaOx NL, Normal plasma calcium (total 2.34; ionized 1.23) Normal PTH (31) Low 25-Vit D (12) Normal 1,25-Vit D (51) Hypercalciuria (8.2)	Idiopathic NL	(Infantile) HC/NL
5589	*CYP24A1*	AD/AR	het	c.428_430del	p.Glu143del	LP	NM_000782.5 rs777676129	M	21-25	2	70 COM, 30 COD	Y	CaOx NL, Normal plasma calcium (total 2.21; ionized 1.23) Normal PTH (43) Low 25-Vit D (62) Normal 1,25-Vit D (67) Hypercalciuria (5.6)	Idiopathic NL	(Infantile) HC/NL
5711	*CYP24A1*	AD/AR	het	c.1186C>T	p.Arg396Trp	P	NM_000782.5 rs114368325	M	26-30	5	100 COM	Y	CaOx NL, Normal plasma calcium (total 2.38; ionized 1.21) Normal PTH (28) Normal 25-Vit D (84) Normal 1,25-Vit D (108) Hypercalciuria (6.9)	Idiopathic NL	(Infantile) HC/NL
5752	*CYP24A1*	AD/AR	het	c.1315C>T	p.Arg439Cys	LP	NM_000782.5 rs374292194	M	41-45	4	1) 90 COD, 5 COM, 5 CA 2) 90 COD, 5 COM, 5 CA	Y	CaOx NL, Osteoporosis Normal plasma calcium (total 2.09; ionized 1.19) Normal PTH (36) Normal 25-Vit D (52) Normal 1,25-Vit D (103) Hypercalciuria (5.8)	Idiopathic NL	(Infantile) HC/NL
5794	*CYP24A1*	AD/AR	hom	c.428_430del	p.Glu143del	LP	NM_000782.5 rs777676129	M	61-65	2	N/A	N	NL, NC, multiple kidney cysts, incomplete dRTA Normal plasma calcium (total 2.49; ionized 1.25)	Medullary sponge kidney	(Infantile) HC/NL

													Low PTH (12) Low 25-Vit D (26) Normal 1,25-Vit D (73) Hypercalciuria (10.2)		
5803	*CYP24A1*	AD/AR	het	c.1226T>C	p.Leu409Ser	LP	NM_000782.5 rs6068812	M	26-30	2	60 COD, 20 COM, 20 CA	N	CaOx NL Normal plasma calcium (total 2.29) Normal PTH (31) Normal 25-Vit D (59) Normal 1,25-Vit D (186) Hypercalciuria (8.3)	Idiopathic NL, incomplete dRTA, medullary NC	(Infantile) HC/NL

CLDN16 – Familial hypomagnesemia with hypercalciuria & nephrocalcinosis (FHHNC) / CLDN-16 associated kidney stone disease

5001	*CLDN16*	AD/AR	het	c.458A>G	p.Asn153Ser	LP	NM_006580.4 rs201367228	M	41-45	4	N/A	N	NL, Normal plasma calcium (total 2.47; ionized 1.28) Normal plasma magnesium (0.89) Normal PTH (53) Normal 1,25-Vit D (110) Normal urine calcium (4.3) Normal urine magnesium (2.76)	Idiopathic NL	CLDN16-associated kidney stone disease
5039	*CLDN16*	AD/AR	het	c.458A>G	p.Asn153Ser	LP	NM_006580.4 rs201367228	M	16-20	5	90 COD, 10 COM	Y	CaOx NL Normal plasma calcium (total 2.37; ionized 1.19) Normal plasma magnesium (0.86) Normal PTH (40) Normal 1,25-Vit D (148) Hypercalciuria (8.4) Normal urine magnesium (4.82)	Idiopathic NL	CLDN16-associated kidney stone disease
5199	*CLDN16*	AD/AR D	het	c.458A>G	p.Asn153Ser	LP	NM_006580.4 rs201367228	M	36-40	3	80 COM, 20 COD	Y	CaOx NL Normal plasma calcium (total 2.29; ionized 1.2) Normal PTH (49) Low 25-Vit D (10) Low 1,25-Vit D (45) Normal urine calcium (3.7)	Idiopathic NL	CLDN16-associated kidney stone disease
5250	*CLDN16*	AD/AR	het	c.458A>G	p.Asn153Ser	LP	NM_006580.4 rs201367228	F	46-50	3	N/A	Y	NL (radiopaque stones), Osteopenia, Ureter fissus Normal plasma calcium (total 2.21; ionized 1.21) Normal plasma magnesium (0.95) Normal PTH (32) Low 25-Vit D (16) Normal 1,25-Vit D (84)	Idiopathic NL	CLDN16-associated kidney stone disease

													Hypercalciuria (6.7) Normomagnesiuria (4.96)		
5445	*CLDN16*	AD/AR	het	c.458A>G	p.Asn153Ser	LP	NM_006580.4 rs201367228	M	36-40	2	90 COD, 10 COM	N	CaOx NL, Osteopenia Normal plasma calcium (total 2.3; ionized 1.18) Normal plasma magnesium (0.88) Normal PTH (44) Normal 25-Vit D (44) Normal 1,25-Vit D (107) Hypercalciuria (9.1) Normal urine magnesium (5.3)	Idiopathic NL	CLDN16-associated kidney stone disease
5712	*CLDN16*	AD/AR	het	c.458A>G	p.Asn153Ser	LP	NM_006580.4 rs201367228	F	21-25	3	N/A	Y	NL, Osteopenia Normal plasma calcium (total 2.34; ionized 1.18) Normal plasma magnesium (0.79) Normal PTH (32) Normal 25-Vit D (52) Normal 1,25-Vit D (127) Hypercalciuria (7) Normal urine magnesium (4)	Idiopathic NL	CLDN16-associated kidney stone disease
5776	*CLDN16*	AD/AR	het	c.458A>G	p.Asn153Ser	LP	NM_006580.4 rs201367228	M	26-30	2	100 COM	Y	CaOx NL, Osteopenia, Papillary calcification Normal plasma calcium (total 2.36; ionized 1.17) Normal plasma magnesium (0.84) Normal PTH (53) Normal 25-Vit D (67) Normal 1,25-Vit D (111) Hypercalciuria (5.7) Normal urine magnesium (3.7)	Idiopathic NL	CLDN16-associated kidney stone disease
GRHPR – Primary hyperoxaluria, type 2 (PH2)															
5432	*GRHPR*	AR	hom	c.103del	p.Asp35ThrfsTer11	P	NM_012203.2 rs80356708	M	26-30	8	1) 80 COM, 20 COD 2): 90 COM, 10 COD 3): 90 COM, 10 COD	Y	CaOx NL, CKD stage 3 Hyperoxaluria (1796) Low urine glycolate/high urine glycerate Hypocitraturia (1.3)	PH2, start dialysis at age 57	PH2
HOGA1 –Primary hyperoxaluria, type 3 (PH3)															
5595	*HOGA1*	AR	hom	c.700+5G> T	p.?	P	NM_138413.4 rs185803104	M	36-40	5	80 COM, 20 COD	N	CaOx NL, CKD stage 2 Normal urine calcium (2.88)	Idiopathic NL	PH3

													Normal urine oxalate random diet (428-463), high urine oxalate low Ca/Na diet (1090)		
SLC4A1 – AD distal renal tubular acidosis (AD-dRTA)															
5796	*SLC4A1*	AD/AR	het	c.1166G>A	p.Arg389His	LP	NM_000342.4 rs767059191	M	11-15	4	1) 90 COM, 20 COD 2) 100 COM 3) 90 COM, 10 COD 3) 90 COM, 10 COD	N	CaOx NL, DM II Variable urine pH 5.7 – 7.0 Hypocitraturia (1.7) Hyperoxaluria (564) Normal plasma bicarbonate (24) and pH 7.35	Idiopathic NL	AD-dRTA
SLC3A1 – Cystinuria type A															
5030	*SLC3A1*	AD/AR	het	c.1400T>C	p.Met467Thr	P	NM_000341.4 rs121912691	F	16-20	5	80 Cystine, 20 CA	Y	Cystine NL, CKD stage 3, osteoporosis Urine cystine (115-254 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.1617+1G >A	p.?	LP	rs558461213								
5092	*SLC3A1*	AD/AR	het	c.851A>G	p.Asp284Gly	LP	NM_000341.4 -	M	16-20	1	100 Cystine	Y	Cystine NL, Urine cystine (263 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.1617+5G >A	p.?	LP	-								
5094	*SLC3A1*	AD/AR	het	c.1400T>C	p.Met467Thr	P	NM_000341.4 rs121912691	M	51-55	5	1) 90 CA 10 COM 2) 100 cystine	Y	Cystine NL, CKD stage 2, kidney cysts Urine cystine (247 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.809G>A	p.Arg270Gln		rs142358712								
5156	*SLC3A1*	AD/AR	hom	c.1400T>C	p.Met467Thr	P	NM_000341.4 rs121912691	M	21-25	5	100 cystine	Y	Cystine NL Urine cystine (193-235 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
5162	*SLC3A1*	AD/AR	het	c.1400T>C	p.Met467Thr	P	NM_000341.4 rs121912691	F	21-25	5	100 cystine	N	Cystine NL, CKD stage 3 Urine cystine (267-939 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.787A>C	p.Ser263Arg	LP	-								
5168	*SLC3A1*	AD/AR	het	c.851A>G	p.Asp284Gly	LP	NM_000341.4 -	F	16-20	5	1) 100 cystine 2) 100 cystine 3) 90 cystine, 10 CA	Y	Cystine NL Urine cystine (213-435 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A

ID	Gene		Zygosity	cDNA	Protein	Class	Transcript / rsID	Sex	Age	#	Stone composition		Clinical findings		
			het	c.1617+5G>A	p.?	LP	-								
5479	*SLC3A1*	AD/AR	het	c.1400T>C	p.Met467Thr	P	NM_000341.4 rs121912691	F	21-25	3	1) 100 cystine 2) 100 cystine	Y	Cystine NL, CKD stage 2 Urine cystine (191-232 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.1094G>T	p.Arg365Leu	P	rs567478582				See above		See above		
5288	*SLC3A1*	AD/AR	hom	c.647C>T	p.Thr216Met	P	NM_000341.4 rs369641941	F	16-20	5	1)-5) 100 cystine	N	Cystine NL, CKD stage 3 Urine cystine (291-306 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
5578	*SLC3A1*	AD/AR	hom	c.833T>C	p.Phe278Ser	LP	NM_000341.4 rs762218116	M	16-20	18	N/A	N	Cystine NL, CKD stage 3 Urine cystine (145-239 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
SLC7A9 – Cystinuria, type B															
5038	*SLC7A9*	AD/AR	het	c.1316A>G	p.Tyr439Cys	LP	NM_014270.5 -	F	16-20	28	1) 60 cystine, 40 CA 2) 100 cystine	N	Cystine NL, CKD stage 3 Urine cystine (301 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria, type B
			het	c.775G>A	p.Gly259Arg	LP	rs121908483								
5160	*SLC7A9*	AD/AR	hom	c.313G>A	p.Gly105Arg	P	NM_014270.5 rs121908480	M	0-5	4	100 cystine	Y	Cystine NL Urine cystine (286 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria, type B
5211	*SLC7A9*	AD/AR	het	c.313G>A	p.Gly105Arg	P	NM_014270.5 rs121908480	F	41-45	4	90 COM, 10 COD	N	CaOx NL Hypercalciuria (5.3) Normal urine oxalate (237) Urine cystine (57 mmol/mol Creatinine) Norm: <30)	Idiopathic NL	Cystinuria, type B
5412	*SLC7A9*	AD/AR	hom	c.313G>A	p.Gly105Arg	P	NM_014270.5 rs121908480	M	41-45	5	100 cystine	N	Cystine NL Urine cystine (223 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria, type B
5517	*SLC7A9*	AD/AR	het	c.313G>A	p.Gly105Arg	P	NM_014270.5 rs121908480	M	26-30	2	1) 70 COD, 30 CA 2) 10 COM, 60 COD, 30 CA;	Y	CaOx NL Hypercalciuria (8.6) Normal urine oxalate (297) Hypocitraturia (0.2) Urine cystine (59 mmol/mol Creatinine) Norm: <30)	Idiopathic NL	Cystinuria, type B
5678	*SLC7A9*	AD/AR	het	c.749+1G>C	p.?	P	NM_014270.5 rs1060499787	M	41-45	3	80 Brushite, 10 COM, 10 CA	N	Brushite/CaOx NL Hypercalciuria (7.5) Normal urine oxalate (381) Normal urine citrate (4.6)	Idiopathic NL	Cystinuria, type B

													Urine cystine (10 mmol/mol Creatinine) Norm: <30)		
5716	*SLC7A9*	AD/AR	hom	c.313G>A	p.Gly105Arg	P	NM_014270.5 rs121908480	F	16-20	2	100 cystine	Y	Cystine NL Urine cystine (273 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria, type B
SLC12A1 – Bartter syndrome, type 2															
5769	*SLC12A1*	AR	het	c.1493C>T	p.Ala498Val	LP	NM_000338.3 rs1366101480	F	21-25	1	1) 100 CA 2) 20 COD, 20 Struvite, 60 CA 3) 20 COD, 20 Struvite, 60 CA	N	CaP/CaOx NL, NC, CKD stage 2 Low Plasma K (3.3) High plasma bicarbonate (28) High urine pH (7.0) High PTH (88) Low 25-Vit D (22) Normal 1,25-Vit D (114) Hypercalciuria (5.31) Hypocitraturia (1.8) Normal urine oxalate (219)	Idiopathic NL and NC, CKD, incomplete dRTA	Bartter syndrome, type 2
			het	c.1878G>A	p.Trp626Ter	LP	rs768765027								
SLC34A1 – Hypophosphatemic nephrolithiasis/osteoporosis-1 (NPHLOP1)															
5181	*SLC34A1*	AD/AR	het	c.1130dup	p.Lys378GlnfsTer61	LP	NM_003052.5 -	F	26-30	2	60 CA, 20 COD, 20 MAP	Y	CaP/CaOx NL, NC, CKD stage 3 Normal plasma calcium (total 2.46, ionized 1.22) Normal plasma phosphate (1.05) Normal PTH (23) Normal 25-Vit D (64) Normal 1,25-Vit D (61) Normal urine calcium (2.86) Hypocitraturia (0.2) High urine oxalate (854) Normal urine phosphate (25.4) No glucosuria, normal urine cystine (4)	Idiopathic NL and NC, CKD	NPHLOP1
5663	*SLC34A1*	AD/AR	het	c.244G>T	p.Glu82Ter	P	NM_003052.5 rs377186926	M	36-40	1	1): 90 Brushite, 10 CA, 2): 100 Brushite	N	Brushite NL, NC, CKD stage 2 Normal plasma calcium (total 2.41, ionized 1.24) Normal plasma phosphate (1.05) Normal PTH (42) Normal 25-Vit D (43)	Idiopathic NL and NC, CKD, incomplete dRTA	NPHLOP1

													Normal 1,25-Vit D (85) Hypercalciuria (8.7) Hypocitraturia (0.5) Normal urine oxalate (180) Normal urine phosphate (38.4) No glucosuria, normal urine cystine (4), incomplete dRTA (NH$_4$CL test)		
SLC34A3 – SLC34A3-related kidney stone disease / hypophosphatemic rickets with hypercalciuria (HHRH)															
5021	*SLC34A3*	AD/AR	het	c.496G>A	p.Gly166Ser	LP	NM_001177316.2 rs200536604	M	31-35	3	N/A	Y	NL (radiopaque stones) Normal plasma calcium (total 2.35, ionized 1.23) Low –normal plasma phosphate (0.77-0.95) Normal PTH (46) Normal 1,25-Vit D (94) Hypercalciuria (8.9) High urine phosphate (34.2)	idiopathic NL	SLC34A3-related kidney stone disease
5045	*SLC34A3*	AD/AR	het	c.496G>A	p.Gly166Ser	LP	NM_001177316.2 rs200536604	M	26-30	3	100 CaOx	N	CaOx NL Normal plasma calcium (total 2.48, ionized 1.23) Normal plasma phosphate (1.13) Normal PTH (48) Normal 1,25-Vit D (103) Hypercalciuria (15.5) High urine phosphate (61)	idiopathic NL	SLC34A3-related kidney stone disease
5048	*SLC34A3*	AD/AR	het	c.1055_1058dup	p.Val354ProfsTer240	LP	NM_001177316.2 -	M	N/A	1	N/A	Y	NL, NC Normal plasma calcium (total 2.43, ionized 1.25) Low –plasma phosphate (0.74-1.01) Normal PTH (29) Normal 25-Vit D (71) Normal 1,25-Vit D (71) Normal plasma bicarbonate (28) Hypercalciuria (7.1) Normal urine phosphate (31) Hypocitraturia (1.4) High urine pH (7.5)	NC with medullary sponge kidney, incomplete dRTA	SLC34A3-related kidney stone disease
5050	*SLC34A3*	AD/AR	het	c.1336-25_1336del	p.?	P	NM_001177316.2 rs775093177	M	51-55	4	N/A	N	NL (radiopaque stones) Normal plasma calcium (total 2.53, ionized 1.21)	Idiopathic NL	SLC34A3-related kidney stone disease

													Normal plasma phosphate (0.91-1.15) Normal PTH (47) Normal 1,25-Vit D (142) Normal urine calcium (2.8) Normal urine phosphate (20)		
5070	*SLC34A3*	AD/AR	het	c.1242C>G	p.Tyr414Ter	LP	NM_001177316.2 rs949841477	M	21-25	1	80 COM 20 OCDP	Y	CaOx/CaP NL, osteopenia Normal plasma calcium (total 2.54, ionized 1.26) Normal plasma phosphate (0.95) Normal PTH (18) Normal 1,25-Vit D (144) Hypercalciuria (6.3) Normal urine phosphate (20)	Idiopathic NL	SLC34A3-related kidney stone disease
5079	*SLC34A3*	AD/AR	het	c.1336-25_1336del	p.?	P	NM_001177316.2 rs775093177	M	41-45	4	1) 80 COD 20 COM 2) 80 UA, 10 COD 10 COM	Y	CaOx/UA NL, gout. Normal plasma calcium (total 2.47, ionized 1.26) Normal plasma phosphate (1.06-1.08) Normal PTH (16) Normal 1,25-Vit D (148) Hypercalciuria (6.4) High urine phosphate (38)	Idiopathic NL	SLC34A3-related kidney stone disease
5102	*SLC34A3*	AD/AR	het	c.575C>T	p.Ser192Leu	P	NM_001177316.2 rs199690076	M	21-25	3	80 COD 10 COM 10 CA	Y	CaOx NL Normal plasma calcium (total 2.58, ionized 1.29) Normal plasma phosphate (0.81-0.95) Normal PTH (37) Normal 1,25-Vit D (161) Hypercalciuria (9.4) High urine phosphate (47)	Idiopathic NL	SLC34A3-related kidney stone disease
5164	*SLC34A3*	AD/AR	het	c.496G>A	p.Gly166Ser	LP	NM_001177316.2 rs200536604	M	16-20	1	N/A	Y	NL Normal plasma calcium (total 2.45, ionized 1.24) Normal plasma phosphate (1.11-1.31) Low PTH (13) Normal 1,25-Vit D (132) Hypercalciuria (9.4) High urine phosphate (37)	Idiopathic NL	SLC34A3-related kidney stone disease
5183	*SLC34A3*	AD/AR	het	c.496G>A	p.Gly166Ser	LP	NM_001177316.2 rs200536604	M	21-25	4	1) 35 COM, 30 COD, 35 CA	Y	CaOx/CaP NL Normal plasma calcium (total 2.18) Normal plasma phosphate (0.87)	Idiopathic NL	SLC34A3-related kidney stone disease

										2) 10 COM, 85 COD, 5 CA		Normal PTH (42) Normal 1,25-Vit D (124) Hypercalciuria (8.1) Normal urine phosphate (24)		
5312	*SLC34A3*	AD/AR	het	c.925+20_9 26-48del	p.?		LP	NM_001177316.2 rs1554784044	F	6-10	4	100 CaOx	N	CaOx NL Normal plasma calcium (total 2.42, ionized 1.21) Low-normal plasma phosphate (0.72-0.91) Normal PTH (22) Normal 25-Vit D (68) Normal 1,25-Vit D (141) Hypercalciuria (6.2) Normal urine phosphate (26)	Idiopathic NL	SLC34A3-related kidney stone disease
5363	*SLC34A3*	AD/AR	het	c.1336-25_1336del	p.?		P	NM_001177316.2 rs775093177	M	26-30	2	60 COD 40 COM	Y	CaOx NL Normal plasma calcium (total 2.33, ionized 1.22) Low-normal plasma phosphate (0.75-0.89) Normal PTH (31) Low 25-Vit D (29) Normal 1,25-Vit D (131) Hypercalciuria (9.5) Normal urine phosphate (30)	Idiopathic NL	SLC34A3-related kidney stone disease
5455	*SLC34A3*	AD/AR	het	c.496G>A	p.Gly166Ser		LP	NM_001177316.2 rs200536604	M	N/A	1	N/A	N	NL (radiopaque stones) Normal plasma calcium (total 2.33, ionized 1.24) Normal plasma phosphate (0.84-1.24) Normal PTH (35) Low 25-Vit D (19) Normal 1,25-Vit D (58) Hypercalciuria (6.1) Normal urine phosphate (25)	Idiopathic NL	SLC34A3-related kidney stone disease
5505	*SLC34A3*	AD/AR	het	c.304+2T> C	p.?		P	NM_001177316.2 rs201293634	M	16-20	3	80 COD 20 OCDP	N/A	CaOx/CaP NL Normal plasma calcium (total 2.23, ionized 1.17) Normal plasma phosphate (0.77-0-97) Normal PTH (24) Normal 25-Vit D (54) Normal 1,25-Vit D (84) Hypercalciuria (8.4) Normal urine phosphate (31)	Idiopathic NL	SLC34A3-related kidney stone disease

5640	*SLC34A3*	AD/AR	het	c.1166dup	p.Gln390AlafsTer203	LP	NM_001177316.2 -	F	46-50	2	1) 80 COM 20 COD 2) 60 COM 20 COD 20 CA	N	CaOx NL Normal plasma calcium (total 2.21, ionized 1.17) Normal plasma phosphate (0.82.1.04) Normal PTH (19) Low 25-Vit D (25) Normal 1,25-Vit D (63) Hypercalciuria (13.7) Normal urine phosphate (22)	Idiopathic NL	SLC34A3-related kidney stone disease
5643	*SLC34A3*	AD/AR	het	c.496G>A	p.Gly166Ser	LP	NM_001177316.2 rs200536604	M	16-20	3	50 COM 30 COD 20 CA	Y	CaOx/CaP NL Normal plasma calcium (total 2.44, ionized 1.23) Low plasma phosphate (0.72-0.76) Normal PTH (18) Low 25-Vit D (37) Normal 1,25-Vit D (77) Hypercalciuria (13.5) High urine phosphate (45)	Idiopathic NL	SLC34A3-related kidney stone disease
5828	*SLC34A3*	AD/AR	het	c.133del	p.Trp45GlyfsTer6	LP	NM_001177316.2 -	M	26-30	1	90 COD/10 COM	Y	CaOx NL Normal plasma calcium (total 2.39, ionized 1.19) Normal plasma phosphate (0.81-1.09) Normal PTH (45) Low 25-Vit D (24) Normal 1,25-Vit D (127) Hypercalciuria (8.8) High urine phosphate (33)	Idiopathic NL, dRTA excluded	SLC34A3-related kidney stone disease
5948 **N K S F**	*SLC34A3*	AD/AR	het	c.496G>A	p.Gly166Ser	LP	NM_001177316.2 rs200536604	F	N/A	0	N/A	N	No NL Normal plasma calcium (total 2.4, ionized 1.22) Normal plasma phosphate (0.93-1.02) Normal PTH (39) Normal 25-Vit D (67) High 1,25-Vit D (361) Hypercalciuria (8.1) Normal urine phosphate (19)	**NKSF**	SLC34A3-related renal phosphate loss
6026	*SLC34A3*	AD/AR	het	c.1623G>A	p.Trp541Ter	P	NM_001177316.2 rs762610288	M	56-60	5	1) 95 COM 5 COD 2) COM 3) COM	N	CaOx NL Normal plasma calcium (total 2.51) Normal plasma phosphate (0.85-1.01) Normal PTH (54) Normal 25-Vit D (70)	Idiopathic NL	SLC34A3-related kidney stone disease

Normal 1,25-Vit D (88)
Hypercalciuria (5.3)
Normal urine phosphate
(31)

Normal/pathologic values laboratory parameters:

Plasma calcium (mmol/l): 2.15-2.5

Plasma magnesium (mmol/l): 0.66-1.07

Plasma phosphate (mmol/l): 0.81-1.45

PTH (pg/ml): 15-65

25-Vit D (nmol/l): 50-135

1,25-Vit D (pmol/l): 48-190

Hypercalciuria (mmol/24h): >5

Hyperoxaluria (µmol/24h): >500

Hypocitraturia (mmol/24h): <1.65

Urine magnesium (mmol/24h): 3-5

Urine phosphate (mmol/24h): 13-32

FIGURE LEGENDS

Figure 1: Upper Panel: Flowchart of patient inclusion, exclusion and genetic analysis in the Bern Kidney Stone Registry (BKSR). Data from 1152 individuals recruited into the BKSR were analyzed. After exclusion of individuals without genetic information available, declined consent or multiple inclusions, the analyzed cohort consisted of 901 individuals (787 stone formers (KSF) and 114 non stone forming controls (NKSF). Before inclusion in the BKSR, NKSF underwent ultrasound imaging to exclude nephrolithiasis (NL) and/or nephrocalcinosis (NC). Genetic analysis was performed in a standardized prioritization pathway in 34 known kidney stone genes. n= number of individuals. Genetic Diagnosis: Likely pathogenic or pathogenic variant by ACMG criteria. WES: whole exome sequencing, **Lower Panel: Kidney stone disease gene panel used for genetic analysis.** Panel of 34 known kidney stone genes used, grouped by phenotype / transport function. AD: autosomal dominant, AR: autosomal recessive, XLR: X-linked recessive, XLSD: X-linked semi-dominant. MODY: maturity-onset Diabetes of the Young, FRTS: Fanconi renal tubular syndrome.

Figure 2: Overall yield of genetic diagnoses (A) Diagnostic yield in kidney stone formers (KSF), (B) Diagnostic yield in non stone forming controls (NKSF), (C) distribution of zygosity in kidney stone formers (KSF) (monoallelic vs biallelic), (D) Overview of genetic diagnosis in kidney stone formers (KSF), sorted in genetic/phenotypic groups.

Bern Kidney Stone Registry - WES Flowchart

1152 Individuals in BKSR

WES-Data available

Exclusion criteria
no genetic information (n=198)
multiple inclusion (n=33)
declined consent (n=20)

Inclusion criteria KSF
informed consent, ≥ 1 stone episode, age ≥ 18

KSF (n= 787)

NKSF (n= 114)

Inclusion criteria NKSF
informed consent, no stone episode, no NL or NC at screening, age ≥ 18

Kidney stone gene panel analysis (n = 901)

KSF (n= 787)

NKSF (n= 114)

Genetic diagnosis (n= 66) 8.39%

No genetic diagnosis (n= 721) 91.61%

Genetic diagnosis (n=1) 0.9%

No genetic diagnosis (n=113) 99.1%

Kidney Stone Gene Panel

Calcium Metabolism
ADCY10	AD
CASR	AD
CLCN5	XLSD
CLDN16	AD/AR
CLDN19	AR
CYP24A1	AD/AR
HNF4A	AD (p.R76W)*
OCRL	XLR
VDR	AD

*specific SNV associated with both MODY and FRTS

Renal Tubular Acidosis
ATP6V0A4	AR
ATP6V1B1	AR
ATP6V1C2	AR
CA2	AR
FOXI1	AR
SLC4A1	AD/AR
WDR72	AR

Phosphate Metabolism
SLC9A3R1	AD
SLC34A1	AD/AR
SLC34A3	AD/AR

Uric Acid Metabolism
HPRT1	XLR
SLC2A9	AR
SLC22A12	AD/AR

Bartter Syndrome
CLCNKB	AR
KCNJ1	AR
SLC12A1	AR

Cystinuria
SLC3A1	AR (AD)
SLC7A9	AD/AR

Oxalate Metabolism
AGXT	AR
GRHPR	AR
HOGA1	AR
SLC26A1	AR

Other
APRT	AR
FAM20A	AR
XDH	AR

Diagnostic Yield of KSF

A

91.61%	No genetic diagnosis
8.39%	Genetic diagnosis

Total n = 787

Diagnostic Yield of NKSF

B

99.12%	No genetic diagnosis
0.88%	Genetic diagnosis

Total n= 114

Zygosity of KSF with Genetic Diagnosis

C

68.18%	monoalleic
31.82%	biallelic

Total n = 66

Gene Groups of KSF with Genetic Diagnosis

D

30.30% Calcium metabolism
(*CYP24A1, CLDN16*)

28.79% Phosphate wasting
(*SLC34A1/A3*)

24.24% Cystinuria
(*SLC3A1 & SLC7A9*)

16.67% Other
(*ADCY10, AGXT, ATPV1B1, CASR,
GRHPR, HOGA1, SLC4A1, SLC12A1*)

Total n= 66